Lead Product(s) : Volanesorsen
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy
Details : Waylivra (volanesorsen), an antisense oligonucleotide designed to inhibit the formation of apoC-III, is a product of Ionis Pharmaceuticals, Inc.'s proprietary antisense technology. Waylivra has received conditional marketing approval in the EU as a treat...
Product Name : Waylivra
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
January 12, 2022
Lead Product(s) : Volanesorsen
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable